Skip to content

Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey

Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03363360
Enrollment
2000
Registered
2017-12-06
Start date
2016-12-01
Completion date
2018-12-31
Last updated
2017-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To Assess the Level of Control of Blood Glucose, Blood Pressure, and Blood Lipids Among Patients With Type 2 Diabetes in Jiangxi Province

Brief summary

The study is a multicenter, sub-center contrast, cross-sectional survey.The primary objective of this study was to assess the Comprehensive Awareness and Control of blood glucose, blood pressure, and blood lipids among patients with type 2 diabetes in China Jiangxi. An additional objective was to investigate the impact of hospital type on clinical outcomes.

Detailed description

Background: With the continuous improvement of living standards in the past 30 years, the lifestyle and diet of Chinese people have undergone significant changes, leading to a significant increase in the prevalence of diabetes, hypertension and lipid metabolism disorders. Prevention and control work is also increasingly valued. At present, there is no research on the awareness rates and control rates of blood glucose, blood pressure and blood lipids in diabetic patients in Jiangxi Province. During the 13th Five-Year Plan period, the country has vigorously promoted the grading system of chronic non-communicable diseases, but there is a big gap between the levels of disease management in different levels of hospitals. Methods:The province's multi-center, sub-center control, cross-sectional survey, the number of cases planned to be included in 10000 cases. Patient Access: Within 2 years from the date of the study (December 2016), eligible patients were screened out of outpatients in the participating hospitals, and patients were reviewed and informed of the informed consent.Inclusion criteria: in line with the WHO1999 diabetes diagnostic criteria; age 20-80 years; duration of 1 year or more; signed informed consent. Exclusion criteria: at the same time using other experimental drugs or in other clinical trials; gestational diabetes, other special types of diabetes; in acute infection, trauma and other stress conditions and the acute phase of the disease and other anomalies; patients with malignant tumors.

Interventions

None listed

Sponsors

Second Affiliated Hospital of Nanchang University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 20 years to 80 years who were diagnosed with diabetes according to the World Health Organization criteria, at least 1 years before screening,written informed consent

Exclusion criteria

* Patients if they were pregnant or Other special types of diabetes, Patients with malignant tumor,participating in any other clinical studies, In phase of acute infection, trauma, such as stress state and acute phase of disease and other anomalies

Design outcomes

Primary

MeasureTime frameDescription
HbA1cThe first 30 days or seven days after the visitHbA1c \<7%
TCThe first 30 days or seven days after the visitTC\<5.2mmol/L
TGThe first 30 days or seven days after the visitTG\<1.7mmol/L
LDL-CThe first 30 days or seven days after the visitLDL-C\<3.3mmol/L
HDL-CThe first 30 days or seven days after the visitHDL-C\>1.0mmol/L

Secondary

MeasureTime frameDescription
blood pressureOn the day of the visitsystolic blood pressure \<130 mm Hg, diastolic blood pressure \<80 mm Hg

Countries

China

Contacts

Primary ContactShen YunFeng, professor
1359112481@qq.com18970819455
Backup ContactWang Jun
1359112481@qq.com15797727918

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026